RxDoctor Payments Data

Eddie Patton, MD

Neurology · Houston, TXNPI 1720213770

Payments from drug & device makers

$406,111in general payments, 2019–2025

Across 716 payments — averaging $567.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$106K
  • Biogen$80K
  • Eli Lilly$57K
  • Acadia Pharmaceuticals Inc$40K
  • Argenx US, Inc.$36K
  • Takeda Pharmaceuticals U.S.A., Inc.$34K
  • plus $54K from 38 others
$5,439in research payments, 2019–2025

Across 2 payments — averaging $2719.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

What the payments were for

  • Consulting fees$29,92110%
  • Speaking & faculty fees$214,87972%
  • Travel & lodging$35,20512%
  • Food & beverage$18,2296%
  • Education$5140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406,111 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$487,672
Medicare patients
332
Services billed
4,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$262,704
Rasagiline Mesylate15$2,289
Pyridostigmine Bromide ErPyridostigmine Bromide11$2,011
Memantine Hcl ErMemantine Hcl26$1,749
Pyridostigmine Bromide26$1,390
Gabapentin103$1,339
Donepezil Hcl157$1,264
Pregabalin22$675
Memantine Hcl16$478
Carbidopa-LevodopaCarbidopa/Levodopa26$434
Duloxetine Hcl16$426
ClopidogrelClopidogrel Bisulfate22$230
Levetiracetam12$145
Tramadol Hcl11$112
Fluoxetine Hcl11$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga$360$262,70412 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$123$1,39026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →